Welcome to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
NB: We use cookies to help personalise your web experience and comply with Irish healthcare law. Whatever your choice, you are agreeing to our use of cookies. Please close this browser tab if you don't want to proceed.
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

October 14, 2015


Company: KRKA Pharma Dublin Ltd.
Legal category: Prescription. GMS. Sport permitted.
Active ingredient: Pantoprazole 20mg, 40mg.
Description: Light brownish-yellow, oval, slightly biconvex gastro-resistant tablets.
Presentations: 20mg-28, €8.18; 40mg-28, €15.12.
Indications: Nolpaza 20mg: Adults and adolescents 12 years and above: Symptomatic gastro-oesophageal reflux disease (GORD); long-term management and prevention of relapse in reflux oesophagitis (RO). Adults: Prevention of gastroduodenal ulcers induced by non-selective NSAIDs in patients at risk with a need for continuous NSAID treatment. Nolpaza 40mg: Adults and adolescents 12 years and above: Reflux oesophagitis. Adults: Eradication of H. pylori in combination with appropriate antibiotic therapy in patients with H. pylori associated ulcers; gastric and duodenal ulcer; Zollinger-Ellison-Syndrome (ZES) and other pathological hypersecretory conditions.
Pharmacology: Proton pump inhibitor. Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific action on the proton pumps of the parietal cells.
Dosage: Adult: GORD: 20mg daily for 2-4 weeks; if relief not sufficient, may be taken for a further 4 weeks.  Maintenance, 20mg when required. RO (long-term, prevention of relapse): 20mg daily. Increase to 40mg daily if relapse occurs. Prevention of NSAID-induced gastroduodenal ulcers: 20mg daily. Gastric ulcer and RO: 40mg daily for 4 weeks; dose may be doubled when there has been no response to other treatment; duration may be extended by a further 4 weeks. Duodenal ulcer: 40mg daily for 2 weeks; dose may be doubled when there has been no response to other treatment; duration may be extended by a further 2 weeks. Eradication of H. pylori: 40mg twice daily in combination with either amoxicillin 1g twice daily + clarithromycin 500mg twice daily or clarithromycin 250-500mg + metronidazole 400-500mg (or 500mg tinidazole) twice daily or amoxicillin 1g twice daily + metronidazole 400-500mg (or 500mg tinidazole) twice daily. ZES and other hypersecretory conditions: Initially 80mg daily; with doses >80mg daily, divide dose and give twice daily; may be temporarily increased to >160mg (no longer than required for adequate acid control). Severe hepatic impairment: Maximum 20mg daily. Elderly: As per adults. Children: 12 years and above, RO and GORD only, as per adults. Under 12 years, not recommended.
Contraindications: Hypersensitivity to the active substance, substituted benzimidazoles, sorbitol or to any of the other excipients. Pregnancy (unless necessary). 40mg tablets: Severe hepatic insufficiency or renal impairment (in combination therapy for the eradication of H. pylori).
Special precautions: Exclude malignant disease of the oesophagus or stomach prior to treatment. May lead to a slightly increased risk of GI infections (e.g. Salmonella and Campylobacter. Investigate patients who do not respond to treatment. Caution: Severe liver impairment (monitor liver enzymes regularly, discontinue if levels increase), long-term treatment (regular surveillance). May reduce vitamin B12 absorption. Lactation (only if benefit outweighs risk). Contains sorbitol.
Drug interactions: Not recommended: Atazanavir (if unavoidable close clinical monitoring recommended; increase atazanavir dose to 400mg with 100mg of ritonavir). Caution: Drugs with pH-dependent bioavailability (e.g. ketoconazole, itraconazole, posaconazole, erlotinib), coumarin-type anticoagulants.
Adverse drug reactions: Headache, diarrhoea.

Full prescribing information and references available from KRKA Pharma Dublin Ltd.